UnitedHealth Group

UnitedHealth Group Faces Scrutiny Over Medicare Practices

Eli Lilly

Boston Scientific

Healthcare Stocks in Focus: Eli Lilly, UnitedHealth, Boston Scientific, Dow Jones and S&P 500 End Week with Modest Losses

Trov Solutions targets 10% EPS growth for FY23, forecasts UnitedHealth Group impact through 2007.

UnitedHealth Faces New Medicare Accusations, What Does it Mean for UNH Stock?

联合健康

UnitedHealth Group's 15min chart triggered MACD Death Cross, KDJ Death Cross.

Catalyst<ul> <li>Analysts have rated UNH as Buy, showing broad institutional optimism about its future performance.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flow analysis indicates negative trends in medium, large, and extra-large investment buckets, reflecting a lack of confidence among larger investors.</li> <li>Bearish technical signals are obviously dominant, with two bearish indicators and no bullish signals in recent data.</li></ul>

Key Factors

UnitedHealth posted adjusted EPS of $2.92, beating estimates but facing a 51% year-over-year drop in operating income to $4.3 billion. UnitedHealth faces accusations of using aggressive tactics to maximize Medicare Advantage payments, including advanced AI and high-tech scanning for higher reimbursements. UnitedHealth shares fell 2.34% to $340.51 amid regulatory scrutiny and Bernstein’s $444.00 price target, with $2.63 billion in trading volume on January 16, 2026. UnitedHealth’s 15-minute chart triggered a MACD and KDJ death cross on January 16, 2026, signaling potential continued downside momentum. UnitedHealth shares rose 1% following President Trump’s healthcare plan announcement, as investors priced in favorable regulatory shifts for insurers.

Recent Updates

UNH News